Skip to content

Real-world study of Qingxuan Zhike Granules in the treatment of acute bronchitis in children

Real-world study of Qingxuan Zhike Granules in the treatment of acute bronchitis in children

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025001632
Enrollment
Unknown
Registered
2025-09-01
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute bronchitis

Interventions

combination therapy group:Conventional Western medical treatment plus Qingxuan Zhike Granules
Conventional treatment group:Conventional Western medical treatment

Sponsors

Beijing Children's Hospital Capital Medical University National Center for Children's Health
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1)The patient's symptoms align with the Western medical diagnostic criteria for acute bronchitis in children. 2)According to the principles of traditional Chinese medicine the condition in question is classified as a cough resulting from wind-heat invading the lung syndrome. 3)Bronchitis duration = 48 hours. 4)Laboratory tests: Complete blood count: Total white blood cell count = 12 × 109/L and neutrophil percentage = 70% C-reactive protein = 12 mg/L 5)Complete rapid direct antigen testing or nucleic acid testing for viral pathogens using nasal/pharyngeal swabs. 6)Age: 1 to 14 years old. 7)Informed consent and voluntary participation are fundamental principles in this context. The process of obtaining informed consent is subject to the regulations outlined in the Good Clinical Practice (GCP) guidelines. Children aged eight years or older are required to sign the informed consent form in conjunction with their legal guardian.

Exclusion criteria

Exclusion criteria: 1)Suffering from acute infectious diseases such as measles and whooping cough 2)Combined severe underlying diseases of the heart, liver, kidneys, digestive system, hematopoietic system, immune system and connective tissue system etc. 3)Cough caused by other conditions (such as bronchial foreign bodies, cough-variant asthma, allergic cough, etc.) 4)Allergic to drugs included in the treatment regimen;

Design outcomes

Primary

MeasureTime frame
Time taken for cough to disappear;Time to onset of cough relief;Evaluation of efficacy for main symptoms;

Secondary

MeasureTime frame
Change in total score for acute bronchitis symptoms;Incidence of pneumonia;Compliance;

Countries

China

Contacts

Public ContactYang yan

Beijing Children's Hospital, Capital Medical University, National Center for Children's Health

yy2303@sina.com13370115027

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026